Baidu
map

Clinica Chimica Acta:特定年龄儿童血浆游离去甲肾上腺素、去甲肾上腺素、3-甲氧基酪胺和甲基多巴的参考区间

2019-09-13 gladiator MedSci原创

在儿科中,可能会缺乏可用的生化测试参考区间,这也可能对生化测试造成很大困难。在此,我们建立了儿茶酚胺<span lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:14.0pt;font-family:"Calibri","sans-serif"; mso-fareast-font-family:

在儿科中,可能会缺乏可用的生化测试参考区间,这也可能对生化测试造成很大困难。在此,我们建立了儿茶酚胺o -甲基化代谢物的年龄特异性连续参考区间,用于评估产生儿茶酚胺的肿瘤儿童,特别是怀疑为神经母细胞瘤的年幼儿童

研究人员在5332日龄至18岁的儿童中,通过液相色谱串联质谱法分析了3-甲氧基酪胺,去甲变肾上腺素,变肾上腺素和3-O-甲基多巴的血浆浓度。

新生儿直到六个月大婴儿血浆游离去甲变肾上腺素,3-甲氧基酪胺和3-O-甲基多巴的浓度较高,但此后急剧下降,一年后低于新生儿浓度的38%,并在青少年进一步降低为新生儿的<23%。相反,血浆中游离甲肾上腺素的浓度呈现出一种相反模式,一岁以下的婴儿血浆中游离甲肾上腺素的浓度比一岁以后的儿童低50%

儿童早期血浆中去甲肾上腺素、3-甲氧基酪氨酸和3- o -甲基多巴浓度与甲肾上腺素的动态变化表明,由于肾上腺外和肾上腺嗜铬细胞组织发生了潜在的发育变化,必须在儿童参考区间加以考虑,尤其是在婴儿中。有了这样的参考区间,儿童产生儿茶酚胺肿瘤的生化检测将会得到了显著改善。

原始出处:

Mirko PeitzschAnastasios MangelisAge-specific pediatric reference intervals for plasma free normetanephrine, metanephrine, 3-methoxytyramine and 3-O-methyldopa: Particular importance for early infancy

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849702, encodeId=412a1849e020e, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu May 14 01:52:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745943, encodeId=b1b71e4594346, content=<a href='/topic/show?id=2ede69e86a4' target=_blank style='color:#2F92EE;'>#甲基多巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69786, encryptionId=2ede69e86a4, topicName=甲基多巴)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 04 02:52:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895186, encodeId=407918951869d, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Wed Jun 24 08:52:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284931, encodeId=94a312849318e, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Sep 15 12:52:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546906, encodeId=848f1546906e5, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Sun Sep 15 12:52:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372708, encodeId=777e3e2708dd, content=非常值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39cf1515565, createdName=libaojian123, createdTime=Sat Sep 14 10:56:20 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372695, encodeId=5a8d3e26957e, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Sep 14 06:55:21 CST 2019, time=2019-09-14, status=1, ipAttribution=)]
    2020-05-14 windight
  2. [GetPortalCommentsPageByObjectIdResponse(id=1849702, encodeId=412a1849e020e, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu May 14 01:52:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745943, encodeId=b1b71e4594346, content=<a href='/topic/show?id=2ede69e86a4' target=_blank style='color:#2F92EE;'>#甲基多巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69786, encryptionId=2ede69e86a4, topicName=甲基多巴)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 04 02:52:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895186, encodeId=407918951869d, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Wed Jun 24 08:52:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284931, encodeId=94a312849318e, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Sep 15 12:52:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546906, encodeId=848f1546906e5, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Sun Sep 15 12:52:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372708, encodeId=777e3e2708dd, content=非常值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39cf1515565, createdName=libaojian123, createdTime=Sat Sep 14 10:56:20 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372695, encodeId=5a8d3e26957e, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Sep 14 06:55:21 CST 2019, time=2019-09-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1849702, encodeId=412a1849e020e, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu May 14 01:52:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745943, encodeId=b1b71e4594346, content=<a href='/topic/show?id=2ede69e86a4' target=_blank style='color:#2F92EE;'>#甲基多巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69786, encryptionId=2ede69e86a4, topicName=甲基多巴)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 04 02:52:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895186, encodeId=407918951869d, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Wed Jun 24 08:52:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284931, encodeId=94a312849318e, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Sep 15 12:52:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546906, encodeId=848f1546906e5, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Sun Sep 15 12:52:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372708, encodeId=777e3e2708dd, content=非常值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39cf1515565, createdName=libaojian123, createdTime=Sat Sep 14 10:56:20 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372695, encodeId=5a8d3e26957e, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Sep 14 06:55:21 CST 2019, time=2019-09-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1849702, encodeId=412a1849e020e, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu May 14 01:52:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745943, encodeId=b1b71e4594346, content=<a href='/topic/show?id=2ede69e86a4' target=_blank style='color:#2F92EE;'>#甲基多巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69786, encryptionId=2ede69e86a4, topicName=甲基多巴)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 04 02:52:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895186, encodeId=407918951869d, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Wed Jun 24 08:52:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284931, encodeId=94a312849318e, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Sep 15 12:52:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546906, encodeId=848f1546906e5, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Sun Sep 15 12:52:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372708, encodeId=777e3e2708dd, content=非常值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39cf1515565, createdName=libaojian123, createdTime=Sat Sep 14 10:56:20 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372695, encodeId=5a8d3e26957e, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Sep 14 06:55:21 CST 2019, time=2019-09-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1849702, encodeId=412a1849e020e, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu May 14 01:52:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745943, encodeId=b1b71e4594346, content=<a href='/topic/show?id=2ede69e86a4' target=_blank style='color:#2F92EE;'>#甲基多巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69786, encryptionId=2ede69e86a4, topicName=甲基多巴)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 04 02:52:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895186, encodeId=407918951869d, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Wed Jun 24 08:52:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284931, encodeId=94a312849318e, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Sep 15 12:52:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546906, encodeId=848f1546906e5, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Sun Sep 15 12:52:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372708, encodeId=777e3e2708dd, content=非常值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39cf1515565, createdName=libaojian123, createdTime=Sat Sep 14 10:56:20 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372695, encodeId=5a8d3e26957e, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Sep 14 06:55:21 CST 2019, time=2019-09-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1849702, encodeId=412a1849e020e, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu May 14 01:52:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745943, encodeId=b1b71e4594346, content=<a href='/topic/show?id=2ede69e86a4' target=_blank style='color:#2F92EE;'>#甲基多巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69786, encryptionId=2ede69e86a4, topicName=甲基多巴)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 04 02:52:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895186, encodeId=407918951869d, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Wed Jun 24 08:52:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284931, encodeId=94a312849318e, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Sep 15 12:52:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546906, encodeId=848f1546906e5, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Sun Sep 15 12:52:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372708, encodeId=777e3e2708dd, content=非常值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39cf1515565, createdName=libaojian123, createdTime=Sat Sep 14 10:56:20 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372695, encodeId=5a8d3e26957e, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Sep 14 06:55:21 CST 2019, time=2019-09-14, status=1, ipAttribution=)]
    2019-09-14 libaojian123

    非常值得学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1849702, encodeId=412a1849e020e, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu May 14 01:52:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745943, encodeId=b1b71e4594346, content=<a href='/topic/show?id=2ede69e86a4' target=_blank style='color:#2F92EE;'>#甲基多巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69786, encryptionId=2ede69e86a4, topicName=甲基多巴)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 04 02:52:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895186, encodeId=407918951869d, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Wed Jun 24 08:52:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284931, encodeId=94a312849318e, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Sep 15 12:52:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546906, encodeId=848f1546906e5, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Sun Sep 15 12:52:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372708, encodeId=777e3e2708dd, content=非常值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39cf1515565, createdName=libaojian123, createdTime=Sat Sep 14 10:56:20 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372695, encodeId=5a8d3e26957e, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Sep 14 06:55:21 CST 2019, time=2019-09-14, status=1, ipAttribution=)]
    2019-09-14 txqjm

    谢谢了,学习

    0

相关资讯

JCLA:采用中国浙江省中国人口数据建立临床检测参考区间

近日,国际杂志 《Journal of Clinical Laboratory Analysis》上在线发表一项关于采用中国浙江省中国人口数据建立Beckman Coulter DxI-800分析仪血清甲状腺激素,游离甲状腺素和总甲状腺素的免费和总三碘甲状腺原氨酸的参考区间的研究。

CCLM:在多中心研究的基础上建立健康中国成年男性性激素和SHBG的参考区间

性激素测定对于诸如睾丸功能障碍、男性不育和女性化综合症等健康问题至关重要。然而,目前在中国男性中没有关于参考区间(RIs)的报告。我们在全国范围内开展了一项多中心研究,建立了七种性激素的参考区间,包括促黄体生成素[LH]、促卵泡激素[FSH]、催乳素[PRL]、总睾酮[TT]、游离睾酮[FT]、生物可利用睾酮[BAT]和雌激素[E2]以及性激素结合球蛋白[SHBG]。 研究人员于2013年,

CLIN CHEM:血清甲状腺刺激激素测量的统一为采用更一致的参考区间铺平了道路

IFCC甲状腺功能测试标准化委员会制定了促进甲状腺激素测量的全球统一标准方法。它是基于对临床血清样本的一个多种方法比较研究和以稳定因子分析方法的目的设置。在此,研究人员对进行的IV期方法比较和参考区间(RI)进行描述,目的是重新校准参与测定并证明概念验证。

CCLM:在健康的CALIPER队列中使用DiaSorin LIAISON XL测定1,25-二羟基维生素D的儿科参考区间

1,25-二羟基维生素D(1,25(OH)2 D)是一种生物活性维生素D代谢物,在钙和磷酸盐稳态中起着关键作用。测量1,25(OH)2 D可评估钙和磷酸盐代谢,特别是在高速生长和发育期间。尽管其非常重要,但目前尚无可靠的儿科参考区间,且可使用的参考范围也是基于成人人群或过时的方法而开发的。我们使用DiaSorin的全自动化学发光免疫测定法,对来自CALIPER队列的健康儿童和青少年建立了1,25(

Baidu
map
Baidu
map
Baidu
map